For people with multiple sclerosis (MS) on Ocrevus (ocrelizumab) whose disease is well controlled after at least a year of treatment, discontinuing the infusion therapy does not appear to increase the risk of new disease activity or disability progression for about two years. That’s according to a new retrospective…
A genetic variant strongly linked to Alzheimer’s disease may also worsen neurological damage in people with multiple sclerosis (MS), according to a new study. Researchers found that MS patients carrying the APOE4 variant showed greater signs of neurodegeneration than those without it, including higher levels of nerve damage biomarkers,…
Most people with multiple sclerosis (MS) have persistently high levels of antibodies against Epstein-Barr virus (EBV), but these antibodies are much less common in people with other neuroinflammatory diseases and in healthy people, a study found “This study indicates that serial testing for EBV-specific antibodies could serve as…
While many genetic factors that increase the risk of multiple sclerosis (MS) are shared across ancestral backgrounds, a study identified a variant that may reduce MS risk in South Asian people, which had not been seen in European studies — suggesting that studies focusing mainly on people of European descent…
Immunic Therapeutics has been granted a new patent in Europe covering multiple dosing regimens of its experimental therapy vidofludimus calcium and related molecules for multiple sclerosis (MS) and other indications. The patent, titled “Dosage Regimen of Vidofludimus for Use in the Treatment of a Chronic Inflammatory…
Get regular updates to your inbox.
